Drug intelligence / Profile preview

MVT-1916

Development stage: Preclinical
Lead developer: MabVax Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MVT-1916 is a radioimmunotherapy (RIT) agent developed for the treatment of pancreatic cancer and other CA19-9 positive malignancies. It consists of the fully human monoclonal antibody HuMab-5B1 (also known as MVT-5873), which specifically targets the sialyl Lewis A (sLea) epitope on the CA19-9 antigen. The antibody is conjugated with the chelator CHX-A″-DTPA and radiolabeled with the beta-emitting isotope Yttrium-90 (90Y). In preclinical studies, MVT-1916 demonstrated significant antitumor efficacy in human pancreatic tumor xenograft models. While its sister compound MVT-1075 (labeled with Lutetium-177) was prioritized for clinical development due to its favorable half-life and utility for biodistribution assessments, MVT-1916 served as a key therapeutic candidate in the MabVax Therapeutics pipeline.

Other names: 90Y-MVT-587390Y-HuMab-5B1

Targets

CA19-9 (Carbohydrate antigen 19-9)

Beyond the preview

Go deeper on MVT-1916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVT-1916.

Explore the full profile